Notably, several p38 inhibitors (e.g., losmapimod, talmapimod, SB203580) have already entered clinical trials for inflammatory conditions such as rheumatoid arthritis and COPD [28, 29]. This evidence concerns the gene MAPK14 and rheumatoid arthritis.